Industry News
Biotechnology Industry News
Eli Lilly took to the stage at the…
Eli Lilly took to the stage at the American Society of Clinical Oncology meeting in Chicago to share early data for a new drug candidate that could, if all goes right, challenge the dominance of
Bristol Myers Squibb may have gone…
Bristol Myers Squibb may have gone big in its pursuit of cereblon E3 ligase modulator (CELMoD) drugs, but today the pharma is standing tall.
With unmet need still high in AML,…
With unmet need still high in AML, new approaches are exploring whether engaging immune responses could help improve long-term disease control.
The FDA has delayed its approval…
The FDA has delayed its approval decision on Beren Therapeutics’ rare disease drug candidate, extending the asset’s long path toward the U.S. market.
Hoth Therapeutics’ search for…
Hoth Therapeutics’ search for salvation in the stars appears to have been rewarded by investors, as the company’s stock doubled after a pivot to powering AI in space.
Regulatory shifts, tight capital…
Regulatory shifts, tight capital and volatile IPO windows are reshaping biopharma strategy. Hear how leaders are adapting.
Tighter capital, higher…
Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.
GSK is pulling back the curtain on…
GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials were functionally cured of the virus.
D&D Pharmatech has linked its…
D&D Pharmatech has linked its GLP-1/glucagon receptor agonist to improvements in liver health, keeping the Korean biotech in the hunt for a market already served by Novo Nordisk’s Wegovy.
Apogee Therapeutics has secured a…
Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.
Kardigan may have only launched…
Kardigan may have only launched last year, but it seems the cardiovascular-focused biotech is already eyeing the public markets.
Amid an intensifying debate over…
Amid an intensifying debate over how Washington should counter China’s rapid ascent in the biotech sector, a growing chorus of policymakers and biotech insiders is urging the Treasury Department to expand the newly codified COINS
As the FDA adjusts to life without…
As the FDA adjusts to life without Marty Makary, M.D., who resigned as commissioner two weeks ago, the numerous policy reforms he put in motion remain intact, including the controversial Commissioner’s National Priority Voucher (CNPV)
Kura Oncology has published early…
Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug candidate to response rates of up to 69% when given with the KRAS inhibitor.
Novartis may be launching an array…
Novartis may be launching an array of vehicles to shuttle drugs across the blood-brain barrier, but executives told Fierce the Swiss pharma is “always looking” for new ways to traverse this final frontier of neuroscience.
Eli Lilly has splashed up to $3.8…
Eli Lilly has splashed up to $3.8 billion on an infectious disease pipeline, acquiring Curevo, LimmaTech Biologics and Vaccine Company to extend its shopping spree into viral and bacterial pathogen R&D.
Faced with a future of evaporating…
Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing to tighten its belt.
For biopharmaceutical companies,…
For biopharmaceutical companies, Japan is one of the world’s most important markets, but also among the most operationally complex. Many therapies with strong global clinical validation still face significant barriers to successful market entry, not
Recorded at Fierce Biotech Week in…
Recorded at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with BioAge co-founder and CEO Kristen Fortney on aging biology, inflammation and why BioAge believes its oral NLRP3 inhibitor
It’s been more than four years…
It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therapies.